CLINICAL_TRIALS
trial_result
· 2022-08-24
Clinical Trial Update: Open-Label Extension and Safety Study of Talazoparib [Phase 2]
Summary
Open-label extension and safety study of talazoparib (Phase 2) completed; results posted in 2022.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Cancer | Phase 2 | Status: COMPLETED | Results posted: 2022-08-24